Navigation Links
NeuroPhage Extends Series B to $21.4M
Date:3/8/2012

CAMBRIDGE, Mass., March 8, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman, an Alzheimer's disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team to lead the clinical development of NPT002. The round was completed by existing investors, including Merieux Developpement, Shire, and private investors. The Series B-1 financing brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. The terms of the financing were not disclosed. 

Dr. Richard Fisher, NeuroPhage's CSO said: "The continued support of all of our investors enables us to fully exploit our recent breakthrough around the mechanism of action of NPT002."

About NeuroPhage

NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
2. Forensic research extends detection of cyanide poisoning
3. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
4. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation
7. U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029
8. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
9. ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization
10. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
11. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... May 16, 2017 Telehealth has long ... and something that has been kept completely separate ... But according to   Logicalis Healthcare Solutions , ... IT solutions and managed services provider ( www.us.logicalis.com ... overlooked – interrelationship between telehealth, imaging, and EHR ...
(Date:5/15/2017)... Somerset, N.J. (PRWEB) , ... May 15, 2017 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... biotechnology company focused on rare genetic diseases, to support preclinical and clinical development ...
(Date:5/12/2017)... ARBOR, Mich. , May 12, 2017 ... selected to present at the 36th annual Michigan Growth ... Forum. GreenMark, a Delaware corporation ... be presenting to investors in attendance, including more than ... deliver health benefits to society through biobased targeting technologies. ...
(Date:5/11/2017)... (PRWEB) , ... May 11, 2017 , ... ... rodent neurons both are excellent resources for disease modeling and drug screening. Human ... differentiated into mature neurons for various applications, however, these often contain mixed population ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):